"Making The Leap To Prospective Risk In Value-Based Oncology Care" - Mary Caffrey
As physicians, including oncologists, gain comfort with payment for value, one question keeps popping up: What will it take to move from being rewarded for good results to accepting losses for bad ones? The challenge in getting specialists to join the shift from 1-sided to 2-sided risk is the next big hurdle in healthcare transformation. Making this leap to 2-sided, or prospective, risk was the theme of “Future Perspectives on Oncology Value-Based Care,” a September 27, 2018, presentation of the Institute for Value-Based Medicine (IVBM) that took place at the Sofitel Hotel in New York City. Luis Isola, MD, medical director of Mount Sinai Cancer and professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, agreed that changing the culture starts with the faculty. “You need those faculty believing in the common mission,” he said. Developing clinical ways, determining standards of care, establishing patient conferences, operating tumor boards, integrating clinical trials, and weaving information technology (IT) throughout means the faculty must “buy in” to healthcare transformation from top to bottom.
- Luis Isola, MD, Medical Director, Mount Sinai Cancer, Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai